Inflammatory Disease

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.

Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.

The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more.

NEW YORK — Children that contracted COVID-19 are at risk for developing multisystem inflammatory syndrome, which can present cutaneously, according to a poster presentation here.

Certain new-onset inflammatory rheumatic diseases, including polymyalgia rheumatica and vasculitis, may be triggered by SARS-CoV-2 infection or vaccination against COVID-19, according to data published in RMD Open.

SCOTTSDALE, Ariz. — Future strategies for managing cytokine storm may rely on adequately predicting treatment response, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

CLEVELAND —In this video from the Medical Dermatology Therapy Update II meeting, Florian Rieder, MD, discusses how a medical home for inflammatory diseases could benefit patients.

The American College of Rheumatology has updated its recommendations regarding the COVID-19 vaccine for patients with rheumatic diseases.

In October, Boehringer Ingelheim’s Cyltezo was approved by the FDA as the first interchangeable biosimilar to AbbVie’s Humira.